Objectives: One of the challenges of spine surgery is the need for adequate exposure of the anterolateral spinal column. Improved retractor systems with integrated lighting minimize the need for large thoracotomy, flank, or abdominal incisions. Beginning in 2013, we began using the NuVasive MaXcess System (Fig) with a minimal access lateral incision for thoracic and lumbosacral spine exposures. There is some concern that these small-access approaches are not adequate when bleeding and other complications arise. This study sought to determine the feasibility and usefulness of a minimal access retractor during anterolateral spine exposures and its effect on both intraoperative and postoperative complications.
Objectives: Patients with neurogenic thoracic outlet syndrome (nTOS) live with daily discomfort that may change activities, strain personal relationships, and limit work ability. Although there is no diagnostic test for thoracic outlet syndrome, use of an anterior/middle scalene block has been suggested as a mechanism to identify patients who will have a good response to surgery. This study was designed to determine outcomes for patients with nTOS who respond favorably to the scalene block after first rib resection.
Methods: All patients presenting for TOS are enrolled in a prospective database. At the time of enrollment and at each follow-up visit, patients complete a brief pain inventory, the Short Form-12, and Quick-dash Results: Over a 3 -year period, 210 patients were evaluated for TOS, and 152 of these patients were evaluated for nTOS. Over the study period, 11 patients with no prior treatment underwent an anterior/middle scalene block followed by surgery and had sufficient data for analysis. The mean age of patients was 40 years (range, 29-55 years). Five patients had symptoms for more than 2 years, four patients had symptoms for 1 to 2 years, and two patients had symptoms for less than 12 years. The cause of TOS in seven patients was an identifiable injury, two patients did repetitive motion for work, and one patient did not have a specific inciting incident. No patient had additional cervical ribs. After transaxillary first rib resection and scalenectomy, nine patients reported a partial decrease in symptoms. One patient reported no change, and one patient had an exacerbation of their symptoms after 10 months owing to increased activity. There were no differences in the mean pain scores (5.5 vs 4.4; P ¼ .11) or work ability (6.4 vs 4.6; P ¼ .29) before and after surgery; however, postoperative Quick-Dash scores were significantly improved postoperatively (63.1 vs 46.4; P ¼ .05).
Conclusions: For patients with nTOS, an anterior and middle scalene block can provide prognostic guidance for surgery. In this cohort of nTOS patients, all of whom had a good response to the scalene block, most patients reported partial improvement in symptoms and there was an overall improvement postoperatively using the objective Quick dash measurement. For patient considering TOS surgery, scalene block can predict improvement in symptoms postoperatively. Objectives: Multiple high-flow arteriovenous malformations (AVMs) are the hallmark of Parkes-Weber syndrome (PWS), unlike other low-flow congenital malformations, such as those seen in Klippel-Trenaunay syndrome. These are difficult to treat and surgical resection has historically shown poor outcomes. The aim of this study was to assess the management of PWS in the current era.
Methods: A retrospective review was performed from 2004 to 2017 on all patients presenting to a single institution for the management of PWS. Presentation, techniques, complications, and outcomes were reviewed.
Results: Fourteen patients (50% male) with PWS were seen at our institution and mean age was 19.9 years (range, 4.7-68.8 years). The lower extremity was affected in 12 (86%) and the upper extremity in 2 (14%) patients. All patients presented with pain and swelling in the affected limb. Seven patients (50%) presented with ulcers, of whom three (43%) had extensive wounds. Five patients (36%) had echocardiographic evidence of high-output cardiac failure. All patients underwent angiography with the intention to treat. Three patients (21%) were found to have diffuse arteriovenous communication with no discrete AVM nidus and thus did not undergo intervention. The remaining 11 patients (79%) underwent transcatheter embolization of the AVM's arterial inflow. Six patients (55%) required multiple or staged inflow embolization procedures, with a mean of 3.3 interventions (range, 1-10 interventions). Thirty-six arterial embolization procedures were performed in total. n-Butyl cyanoacrylate adhesive was used in 22 (72%), microspheres in 8 (22%), and a combination of coils and adhesive in 2 (6%) cases. Technical angiographic success was seen in all patients. Six patients (55%) also had interventions to treat the venous component of the malformation, either concomitantly or during a separate procedure. This included radiofrequency ablation in one (17%), coil embolization in one (17%), sodium tetradecyl sulfate (STS) sclerotherapy in two (33%), and a combination of STS, coil embolization, and vein stripping in two (33%) patients. Ten patients (91%) experienced a partial response and one patient (9%) experienced no response to treatment. No patients had a complete response, as expected with the diffuse nature of this disease. There were no periprocedural complications. Two of three patients with complex wounds required major amputations for gangrene, including one above-the-knee and one below-theknee amputation at 128 months and 66 months after the index procedure, respectively.
Conclusions: High-flow AVMs in PWS can be successfully treated by a transcatheter approach. Multiple interventions are usually required. Patients with extensive wounds remain at risk for loss of limb.
Author Disclosures: A. Carroccio: Nothing to disclose; A. M. Conway: Nothing to disclose; G. Giangola: Nothing to disclose; S. Marzban: Nothing to disclose; R. Rosen: Nothing to disclose; H. Short: Nothing to disclose. Objectives: Resistin is a hormone secreted by adipocytes that has been associated with metabolic syndrome and cardiovascular disease. However, less is known on the role of resistin in patients with peripheral artery disease (PAD). The present study seeks to understand the relationship of serum resistin with endothelial function and cardiovascular outcomes in patients with PAD. We hypothesize that increased serum resistin is associated with worse endothelial function and an increased rate of major adverse cardiac events (MACE).
Methods: One-hundred six patients who presented to clinic with complaints of claudication and an ankle-brachial index of <0.9 or history of revascularization for symptomatic PAD were recruited between 2011 and 2016. Patients were excluded if they had acute illness, renal or hepatic disease, or were taking immunosuppressants. Resistin was assayed using commercially available ELISA kits. Endothelial function was measured via brachial artery flow-mediated vasodilation (FMD) at baseline. Incident MACE were identified by subsequent chart review and defined as a composite end point of myocardial infarction, coronary revascularization, stroke, or death from a cardiac cause. Cox proportional hazards models were used to calculate hazard ratios for MACE.
Results: At baseline, despite similar Rutherford scores, medical comorbidities, and medication use, FMD was significantly lower with increasing resistin quartile (I, 9.1 6 3.3%; II, 7.1 6 3.5%; III, 5.8 6 4.0%; IV, 5.6 6 3.5%; P ¼ .002; Fig 1) . In multivariate linear regression, resistin quartiles III and IV predicted lower FMD relative to the first quartile after adjusting for age, race, body mass index, diabetes mellitus, hypertension, estimated glomerular filtration rate, C-reactive protein, and beta-blocker and angiotensin converting enzyme inhibitor use (III, À2.26 [95% CI, À4.51 to À0.01; P ¼ .05]; IV, -2.53 [95% CI, À4.87 to -0.20; P ¼ .03]). During a median follow-up period of 36 months (interquartile range, 29-45), 21 patients experienced the primary end point. In a Cox proportional hazards model adjusted for smoking status, coronary artery disease, and age, resistin was independently associated with an increased rate of MACE (HR, 1.10; 95% CI, 1.00-1.20; P ¼ .04; Fig 2) .
